Efficacy of HFNC Combined With Sequential NIV in Patients With COPD Complicated With Type II Respiratory Failure

NACompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

January 1, 2024

Study Completion Date

January 31, 2024

Conditions
Chronic Obstructive Pulmonary Disease (COPD)Nasal High Flow Oxygen TherapyNoninvasive VentilationRespiratory Failure
Interventions
DEVICE

high-flow nasal cannula oxygen therapy (HFNC) combined with sequential non-invasive ventilation (NIV)

"The control group was treated with NIV routine treatment. During non-invasive ventilation, patients in both the intervention group and the conventional group will receive NIV through a full mask or nasal mask using any of the existing ventilators in the hospital. Usually, the ventilator was set to the pressure support ventilation mode, and the inspiratory pressure was adjusted to the maximum tolerance to obtain the ideal body weight of 6 \~ 8mL / kg of exhaled tidal volume, and the PEEP was set at 3 \~ 5cmH2O. FiO2 in both groups was set to maintain 88% -92% peripheral blood oxygen saturation.~The study group was treated with nasal high-flow oxygen therapy combined with sequential non-invasive ventilation. Patients will receive high-flow oxygen therapy ventilator during the day and in the morning and evening awake time (manufacturer: Hunan Mingkang Zhongjin Medical Technology Co., Ltd., registration number: Xiangji Zhuzhun 20192080049, model: OH60A) treatment. At night (from 10 p.m. to 6"

DEVICE

NIV routine treatment

Usually, the ventilator was set to the pressure support ventilation mode, and the inspiratory pressure was adjusted to the maximum tolerance to obtain the ideal body weight of 6 \~ 8mL / kg of exhaled tidal volume, and the PEEP was set at 3 \~ 5cmH2O. FiO2 in both groups was set to maintain 88% -92% peripheral blood oxygen saturation.

Trial Locations (1)

Unknown

Beijing You'an Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Beijing YouAn Hospital

OTHER

NCT06992479 - Efficacy of HFNC Combined With Sequential NIV in Patients With COPD Complicated With Type II Respiratory Failure | Biotech Hunter | Biotech Hunter